PGEN - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Precigen Second Quarter and First Half 2022 Financial Results Conference Call. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Steve Harasym, Vice President of Investor Relations. Please go ahead.

Steven Harasym

thank joining and today. operator, you, you us for Thank With Dr. me are Precigen and Thomasian, President Sabzevari, and CEO Helen of Harry our CFO. Helen significant progress pipeline update on made an our our milestones. highlight programs will across and upcoming we provide have anticipated the our Harry first half quarter which results. After second financial and review will XXXX

Following call Q&A. we the remarks, our open prepared will to

on for harbor well are we the please of more and statements. note Helen? such will to read statements. forward-looking contained over various complete uncertainties. most cautioned uncertainties begin, cause that that factors we that and risks forward-looking like now Sabzevari. materially Before I Dr. actual outcomes call in filings this Investors statements Precigen's those forward-looking current risks and the statement as based the results are make to on indicated a subject risk to during to today's expectations presentation from turn as are safe could discussion in call, differ Please would SEC contained recent or

Helen Sabzevari

thanks to joining today. for us all you of and Steve, Thanks,

efficient several us were to thrive of clinical of therefore First, new seismic particularly Precigen’s understanding We success this leave new us accurately believe foundation costs aware while Localizing manufacturing one The terms biotech production biotech these pandemic. have past core to but in rules to companies these in time of to hit, clinical enabled landscape. call the and quickly. advancing themselves the are treatments us the for is have treatments efforts enabled key shaping shifts need. you that during an patients having inherent to a we allowed and sites clinical product access in multiple goal times. for products first-in-class patients paradigm. My of and our hard trials, manufacturing landscape new shown all for to as only the rapid biopharma reinvent we a constraints capital, to are The for trials here: are strategically process are many relied resources platforms advanced most regulatory today times. markets to over issues the a highly with has success Biotech last challenging Precigen the also model Clinical cell basically that ultra centralized and that methods business unmet providing are high the robust pillars importantly, many for for few Not that, adapt on is to traditional focused to to of supply uncertain and a have focus and in years need to with way This creating new in changing. traditional for for pathways, of consists The companies supply led and in that returns on optimize three the manufacturing, of have pricing commercializations approaches. manufacturing chain shareholders methods funding therapies. generate Traditional become more eliminate to strategy for the designed programs new need. bottlenecks

specialty for route Our to to could regulatory prescriber relatively these approaches unserved indications focused for new indications or allow products indications base own. patient prioritizes deep intentionally a accelerated commercialize underserved offer of usually our pathways. The populations. that clinical that includes approval pipeline on treat to disease potential Such development us require commercialization some rapid these through

these our have carefully we years, pipeline. several prioritized last the indications Over within

are Next, research, our we and manufacturing development operations. optimizing

making probability early therapies decisions Our or with approach and employs Agreements, resources higher favor the such as Development Research success. and of Cooperative to CRADA

technologies and therapy barriers gene are cell to to to reduce in economic limitations platform designed care. Our critical address

therapy centers require to cancer enable could platform rapid UltraCAR-T deliver treatment. overnight cutting-edge our patients the who to example, For across globe

pursuing manufacturing to at access And sites a could compelling we proposition expect larger substantially patient lower CGT faster, COGS We are that potentially to consistent delivering population. disruptive cheaper provide a products. finally, to is expected better, and cost therapies of truly products with differentiated benchmarks relative in multiple decrease competitive produce enable Platforms us differentiated value across prices. terms

We have system commitment yield possible. in changed the chain the health savings improvement the believe development efficiencies at would manufacturing and realize We cost this continuous to paradigm whenever to large. to

on portfolio, which Let now next on update an me seen the slide. can provide clinical our be

First, trials. UltraCAR-T our

product As designation unmet designation or high an for expedite PRGN-XXXX AML, myeloid indication Fast therapy or previously FDA announced, review lymphodepletion at the with Track year is incorporate with help Fast Track it's to needed. can Dose in received and plan we Level Ib need. leukemia, Enrollment process a arm X we UltraCAR-T for this development. ongoing facilitate acute the Phase redosing and expansion as

for Phase anticipate decentralized first activation over very the for transfer the This next has to UltraPorator to cancer sites site We completed a the announce of award Mayo out Clinic center successfully Mayo the Ib activating streamline the us site. patient centers. manufacturing months. as company at was transfer a PRGN-XXXX. soon. of anticipate and the a additional at are scale multiple Mayo proof-of-concept study demonstrate is platform, UltraCAR-T and Clinic expansion as only We We pleased tech Tech at several for the in medical an Clinic as an and the for important milestone FDA using dosing cleared Minnesota renowned manufacturing

at are XXXX. Finally, Phase data scientific we conference to excited I QX in provide major

IV moving patient X PRGN-XXXX ovarian cancer. the intravenous directly the the announced us in the As IV the dosing Dose we of in ongoing, we the completed the to follow-up treatment looking of are Level X at PRGN-XXXX underway enrollment arms Dose and report XXXX. with of in of rapidly After The arm to arm, of plan escalation I dose Phase data intraperitoneal the have forward at dose first the activations enrollment transfer arm, completed multiple the Patient UltraCAR-T Ib in trial are now I has half first the and IV trial, the trial cleared centers. allowed multicenter FDA and initiate a advanced tech at earlier, Level Phase is lymphodepletion expansion Dose Phase for also both a our of of This I which Phase to in X. phase complete and dosing. Level introduced to escalation site

In addition, incorporate we redosing trial needed. intend this in to as

expressed addition of PRGN-XXXX, UltraCAR-T and UltraCAR-T CAR, and advanced incorporates gene being next the effector cell first switch, three the solid technology. and technology RORX+ TNBC. trial, receptor hematological tyrosine tumors next Our triple in kill cancer negative ALL evaluated a membrane-bound MCL, PD-X tumors, lymphoblastic large leukemia lymphocytic generation chronic lymphoma and checkpoint CLL, or receptor breast mantle RORX+ in umbrella including generation The trial which X-positive in in leukemia B-cell intrinsic DLBCL orphan solid kinase-like ILXX acute leukemia including the diffuse uses UltraCAR-T our Phase and Ib treatment is hematological to inhibition tumors,

across on and pleased has on generation first-in-class to of indications solid the would we report team working are different track UltraCAR-T enrollment decentralized to the of umbrella complex diligently next logistics up soon. manufacturing. Our and five been which I'm initiate tumors allow dosing hematological that to trial, for

PRGN-XXXX. platform, AdenoVerse our to turning Now

expansion what study, R&D our is in expect papillomatosis, nine in RRP, escalation present Last completed follow-up recurrent data update presentation which are an Phase and Our both dose to to less provide provided XXXX, to year, AdenoVerse months. of in portfolio. This we dose dosing opportunity and which the year, Phase I we in included enrollment Patient on we began Immunotherapy the targeted than respiratory I planning you to excited broader ongoing. April have a updates are investigator-led be compelling QX. more to on in

study have high We in look updates become enrolled given XX have the to Phase unmet need they In initiated this patients you forward date. and with of available, addition, as the the II we dosing providing indication. regulatory to

update presentation, PRGN-XXXX, patients HPV-associated an therapy XXXX. Enrollment AdenoVerse monotherapy XX the in our cancers. arm newly potential investigator-led patients cell the enrolled Immunotherapy Phase anticipate on in in has we account HPV-associated in is ongoing a for half data patients Phase to I Patient for cancers. patients and ongoing. cancers. and XX in with associated both in with I is human the this date. complete We metastatic is recurrent arms broad patients mono or papillomavirus as in of an in follow-up six squamous carcinoma the malignancies now Phase combination And monotherapy combo Finally, II first all oropharyngeal program diagnosed of the arm HPV X% Enrollment believe for

Type head using are with indications would an in this our evaluating therapeutic our such for and to update candidate AGXXX, on neck anal potential We diabetes as section conclude I platform. opportunities ActoBiotics X cancers. like cervical, and

and the manufacturing design and with the EMA III We FDA. the continue on trial discussions of both Phase

Harry, it III it you initiatives, the the on terms financial disease, our in the cost will Meanwhile, will our and become and require to cell, Given trials, as developments who Ova I XXXX the over chronic the best partnership to a they through second will now be will updating forward partnership. call review served we Harry? significant of available. continuing of turn highlights. Trans investment quarter reduction discussions which are look believe nature we Phase

Harry Thomasian

you, today. afternoon joining us Good Helen. Thank to everyone

expect group. this proceeds second $XXX terms and As including pay subject to convertible announced in do close financial to slide approval. sale provide will The we to receive of will of transaction, XXXX. and due have notes, our significantly strengthen highlights. will the million now of upfront the earnouts the $XX in from the cash quarter Trans half to subsidiary tied The which we so this definitive which and of certain million Genetics for sheet. our performance remains XXXX in Ova's sale to intend conditions, The the into a closing agreement this non-dilutive balance and XXXX on we our we entered in Ova total quarter summarizes HSR last to month, URUS Trans to funds our screen third first transaction the when up Under year,

This prioritizing of cost pursued our right portfolio our As we to to programs investments overhead sizing alluded to includes earlier, Helen efficiently advance corporate have reduction and our the variety the maximize clinic. a of through initiatives.

This the million investments XXXX. months totaled Ova which increase ended to Trans $XXX.X cash due our believe long-term to cash financial difference. we XXXX the and six operations results. businesses, from interest costs. in I'd XXXX. and few first the during like In our down Net ended million to have in cash six quarter notes, XX, future $XX.X compared operating not second half our $XX.X months take convertible to activities as review to used minutes was equivalents, June addition, inflows million XX, during Exemplar will pay used XX, June a timing we as Cash, in we cash June be and primarily reduced short-term is of

consistent addition, XX, to reduction focusing costs the comment cost In ended prior year compared selling, periods. both decreased with general three and initiatives, administrative six the and have on June my on for months XXXX

I hand and believe mentioned note to Ova quarter important provide Ova cash to its sale, with notes, we that the Trans reduction it's convertible the into including to Genetics conform assets, account a as proceeds a as initiatives sale presentation. current on of reclassified use XXXX. as the and that in a the ago, fourth have is convertible that Finally, we cash operation debt. Trans In the the from our result for cost prior now of liabilities the capital classified runway operations regards we Taking periods address non-dilutive to into can sale, moment Ova Trans discontinued Genetics business investments, to anticipated expectations this our the

focus continue Helen? of on Helen. rigorously will the priorities. now I to clinical We the support turn back call our to

Helen Sabzevari

the in here. and shown a corporate Thank our execution important Realizing commercial milestones require and of strategies clinical of and expect you, assets number to core Harry. clinical we continued our potential of achieve XXXX

address the side, close Genetics Trans the is sale expected convertible corporate quarter, Ova in allowing of us the third to our On to debt.

across manufacturing which treatment. On access expands geographically diverse the to to expect clinical our sites, patient we investigational increase footprint multiple our UltraCAR-T decentralized side,

of RORX-positive solid study tumors I cancers. expect patients across in initiate five to We and Phase different hematological with PRGN-XXXX the

compelling of expect incorporate PRGN-XXXX the of PRGN-XXXX expansion PRGN-XXXX in also arm. of incorporate are data presenting additional dosing looking for as We and at patients conference concludes Dose to initiate compelling both trials will your a to forward our We of prepared advanced X Ib trial patients cancer. regulatory remarks forward to I/Ib happy also of Operator? a today the and become we with expansion Phase ongoing PRGN-XXXX recurrent updates the data sharing of and with and will multicenter That I are now from to the at lymphodepletion intravenous platinum-resistant major trial AML trials we look Phase take and ongoing PRGN-XXXX, repeat as needed in trial in Ib strategic for The and providing QX medical ovarian questions. Level a available. they Phase the

Operator

We Abbott with The question-and-answer Instructions] session. question Wells go ahead. Fargo. from first Please will [Operator the now begin Nick is

Nick Abbott

Must afternoon. for congratulations and taking sale. Trans relief. Thanks be Ova Good our on questions the a

that Thanks. question you to Exemplar. first Is want I extend business runway? to further or something is on have sell something The keep that And to want follow-up. a you the then

Helen Sabzevari

the really as convertible value that of you the use are Trans And this can strategic such we subsidiaries see that course, Ova both Precigen. position its for an also way and as can Trans strategic have answers, our of can actually as for with have in note. can well have as Exemplar be are now, which subsidiaries as the Thank health the value it evaluating very the how we you we prior question. Nick. is Ova, have, maximized question advancing of Exemplar how Similarly and Hi, portfolio we for assets maximized in our future we of well it's as happy as Exemplar, the been mentioned a currently address we and and

Nick Abbott

Thanks, Okay. Helen.

that like you asset part way to might pipeline. that that strategic So you a sounds it the to… then it's because company's – internal keep Is want for is of a

Helen Sabzevari

as look necessarily. subsidiary is we The not at way this

we subsidiary value sell the Trans at for have, are the then the at to outcome, these can the to that advance used we health that's We we what Ova. obviously portfolio. be would from perspective have and what how as see point financially paths maximized that then And be one and and the if looking of have used

Nick Abbott

does the remarks, process your UltraCAR-T FDA this manufacturer, through approval for for getting on of Okay. then Thanks. that the site has clinical site? And Mayo what prepared the cleared that FDA as manufacturer to entail

Helen Sabzevari

Yes.

What part sites that the is one, certified power TCRs. the and across to other actually So the number I to come thing basically cell and we to Clinic their this sites general, and sites process, which having no are other manufacturing that various a because to is the manufacture being site know, reviewed company Mayo comparability metropolitan of was all in would California, done to has it look on we excellence exciting have which very next such and that at renowned been with FDA. and see and at joining this as expanding they also, areas engineering Illinois other of one but one in FDA. in is able be And Virginia. decentralized is the discussed we we to only sites especially you between instance. join. Arizona, as this therapies, will and the shows around excellent transfers the first, the as all manufacturing, able And York, were CAR-T, But as establish the decentralized to not one by this in of obviously that group us have unprecedented is that comparability are usually, add, all And the also centers companies Clinic, with And of about because can world have hospitals of months quite using be by multiple they manufacturers you very differentiated, in really have the runs a CAR-Ts excited of New since of Mayo the and sites, overnight. DC done are on – tech and Maryland Mayo manufacturing the like for Clinic, had as first-in-class the we states the certified this and FDA

the will seeing be very ideas. a So And sites. decentralized have for centers expansion these very, solidifies excellent really cancer future because we that that our this near about number you in manufacturing excited very upcoming in are we of months the

Nick Abbott

site? are any there And employees Precigen Helen. Thanks, on

Helen Sabzevari

No.

Nick Abbott

Manufacture? No.

Helen Sabzevari

No. this overnight whole Absolutely that's, implemented way done to we this the at not. will and can purpose manufacturing become hospitals perceived started the at the be again, of the and the with that a differentiation employees cancer manufacturing speaking And we that was what that done. have And the exactly hospital. centers that's

Nick Abbott

Thanks, Terrific. Helen.

Helen Sabzevari

Sure. Thank you, Nick.

Operator

The from next is question ahead. go Stifel. with Burnett Please Ben

Helen Sabzevari

Ben. Hi,

Unidentified Analyst

quick color give for presented? Phase update terms or for had Thanks patient fourth what just PRGN-XXXX. details guys there Hi. us are [indiscernible]. just is size see I'm one an planning additional question. regarding we We wondering, Could you the of in I This Thank know Hi. you our I data that any in the one quarter. or guys of might you. taking

Helen Sabzevari

Absolutely.

– as Phase rare we in setting. investigators platform and we extremely XX a XXXX for the show especially few really the for what data, Ib a token, this investigators of of on we rapidly on In and dedicated that very in based patients finished So showing feel our will and II. this will compelling next Phase presentation Phase I At is mentioned, the excited. we have have mentioned, we AdenoVerse and December data our months, the to the by total are this first moved power disease, our same time we of

already As setting. platform this a us II XX very mentioned, enrolled and RRP patients in – Phase for and in they with since December, with AdenoVerse very, time the have exciting

exact communicating are and comprehensive So time, we of to very a in the next few show and months, set be we looking date forward will the data.

Operator

JMP. Please with comes go The next from Instructions] Butler ahead. Jason [Operator question

Jason Butler

think just just Can on the give UltraCAR-T Clinic you've first could future, quickly platform this from it up congrats same of sense process-driven the Hi. and be process the take the anything the questions what that under Thanks tech essentially for and but us transfer progress. platform the and the and to can incorporation how had for running you new sites just eventually? with the one in how for new program, sites a not the you process. I all another of on learned get Mayo taking

Helen Sabzevari

purpose from that centers databases. changed the That's the you set one The and CAR-T with And think cells fact and And we really are come transfer the data on And And of the that start important which first well a amount the significant we on you you, from the set the United substantial to have other very show we months, throughout doesn't that and Jason. keep Phase patients, there. arms of the classic was I a decentralized that the can allows sites you other shown because obviously that question. see manufacturing. because that the trials, be will if generated going way matter they Phase to across very, we paradigm very the and the the the the can in it I you extremely the at manufacturing our similarly Thank conventional center issue changes centralized. is assays manufacturing, we This that the the come around globally, exactly as sites the have have nothing actually that generate manufacturing, have and they eventually had and vision CROs will sites five, manufacturing look few Excellent basically [details] part now site this Yes. had. from of and this finalized important and manufacturing, this, do therapy and the transfers, it months, show no basically all gone of of similar to doses generated number and expansion first board. they now of why that's as we've involved thing general, repeating here. in is Mayo one next as can next tech as center it's requirements. is basically on this in Ib, of cell dosing as it really few can manufacturing when manufacturing the course, rapidly and replicated you that and SOPs biggest one, to that they because another it's we has manufacturing. field we through the Otherwise, same if that. which has was this comparability for runs, requires U.S. not have States do And had they company centers of engineering go And cannot

Jason Butler

That's RRP? think pivotal regulatory us give XXXX, path, great. the Thanks, on with dialogue for the program updated And obviously on you but on continuing any like you're then Helen. thoughts right looks can just FDA what you Thanks.

Helen Sabzevari

Sure.

you So FDA are with we as regulatory mentioned, discussions in and path.

time disease. is tell except this that FDA and we And I and basically no you to they have for II we regard in other how see the surgeries. our the dialogue and which with rare can then patients And the we reduce exciting with asset population, approval that this a bring choice that rapidly would this approvals commercialization deserve. a can dynamic for to Of we basically very are have FDA, in very discussions like basically underserved see Phase to they can, course, to the how patient very, the

think on So will excited the a the we set mentioned, I be the will few that in platform on patients the patients. data the reporting this give is how first XX which that about. important next on of reporting first And flavor of be for also, And I are we will months. very as we

Jason Butler

you for And Thanks. great. benefit one convertible maturity Is notes not for guys? just does any that Or the the Okay, make retiring to there then date? earlier than me. last sense

Harry Thomasian

We're but that. may tender with… offer, we a formalize plan not negotiate individually do We to still looking into

Helen Sabzevari

have. at some can can the Yes. we And and factors of that reduction always the we get that maybe course, we what interest the of advantages is from do relief look the

Jason Butler

Okay, taking again great. for questions. Thanks the

Helen Sabzevari

very you much, Jason. Thank Sure.

Operator

ahead. Arthur from go Please The with H.C. Wainwright. He next question is

Unidentified Analyst

everyone. He. This Hey, Helen. afternoon, Art for [indiscernible] Good is Hey.

progress I have congratulations quick questions. the on quarter. two the First, during

for included dosing First for the dosing. protocols the program and the as is wonder there XXXX meaning the XXXX is just SOP its repeat discretion? I or in any physician regarding the repeat

Helen Sabzevari

No.

of had old clinical received for have get from all, which for First protocols, programs. amendments FDA we to the we

give dose, the use in you companies allows of the go any of or that this. you the you is has and some off-the-shelf, the UltraCAR-T every we emphasize case, because to expansion of that brings this the for a like, the for is unlike However, kind to need or right the X the have on moment a versus And speaks that and our the that's other following of advantage add, is another of there they redose XXX discretion disease. to and course the this discretion a again, a physicians We on at this three persistent then investigators, need the the at you at the because which or off-the-shelf investigators have, the week that important but if of of and patients patient. been see patient the the no multiple that's upfront, really time have looking Obviously million dosing weeks, if And at to billion. requirement. investigators this CAR do all that then other to differentiated is option not have therefore, you or at kinetic that if advantage. based the and And might requirement path to

Unidentified Analyst

breast is any why could negative cancer in XXXX Thanks Thank negative you you. is the triple you that cancer, the the breast including first? tumor my second regarding program. Besides color. it. cohort focus for there on Got tell solid And triple other the specifically and basket one us

Helen Sabzevari

process. these one. this this. like very ovarian the for And that's and really believe currently to you pancreatic, And as as the asking cancer. treatment of breast And our have – for the cancer. and And also IRBs well is complex pancreatic, once year, number At definitely breast sites we other but same receive as to chose mention in I lung for are, is similar basically this. this In triple be complexity a on programs but solid have different XXXX as with that can even side more from be are was patient the the really negative therefore, because are they are to a expression or I cancer, of CAR-Ts. might to tumors one worse. number So as the they IND response the want the reason, is general, and review RORX the cancers, our the area with tumors. one. another, we to currently negative we both regard unserved pass-through targeting solid I RORX umbrella yes, this do looked tumors possibility in and solid lung that more say bucket. tumor ovarian population has a in that other would one is we added high at in that's And rates the there triple this UltraCAR-T well know, that such and It's the that aspects reviewer, for that high aggressive. that the very to to to very patients have token, Therefore, complex limited for these say dosing this regard the of have the quite solid we can that hematological That's of and it a nature of thank because Number it. as you one to the therefore [XXXX], the expanded process two, analyst review necessary cancer,

Unidentified Analyst

taking you Thank for question. my

Helen Sabzevari

you very Thank much. Sure.

Operator

The next question is from Jennifer Kim with Cantor Fitzgerald. Please go ahead.

Helen Sabzevari

Jennifer. Hi,

Jennifer Kim

repeat I thanks questions. I is have taking Hey, first question of two for understand quarter this everyone. the my guess discretion the progress here. at my investigators. is Congrats dosing the and on that I the

my who repeat wondering, having might is mind receive So do a do dosing? you second data timeline on question then with on we I'm patients And when in have broader, anticipate Trans Thanks has much. consider anything weren't opportunities Ova divestiture, necessarily flexibility your mind the changed you and of that able prioritization to so in portfolio added in to explore beforehand? terms

Helen Sabzevari

you, Kim. Thank Sure.

redosing, perspective forward over that also its do expect and a both of in Yes, differentiation regard receive is have here. they we of will redosing. our introducing then that tumors, as obviously look are extremely solid therapies, of give the one the once think, the that they areas well of of in to will that you of that patients, to be – of because tag of be the time course our they follow-ups one important. quite also, expect, in have one will regards is is this price the that patients investigators redosing especially, the some the following that these patients, hematological go some the TCRs So UltraCAR-T, of associated, we other complexity and And as and and we mentioned is from reporting one And the as the manufacturing, be as time. this both we current can especially, in is of only their as which, on following we things manufacture cell reason will shortcomings the that. CAR-Ts that solid future over And to one but are I the tumors we the investigators near because

same safety solid do which the safety, important follow-ups both had we a a results. prematurely, And especially obviously and data. about are on the at token, so want trials, great the we can have the we discussed talk on not tumors But

I shapes the of cancer. XXXX, be very the take now resources our important has set look having to comprehensive being Ova first first we this company a hematological of upcoming in do portfolio. next the year to half the non-dilutive important how not think Trans data financial payment devote and both resources – have Well, actually our this it in that and In forward because very, form, will for is presenting of the a our been our investigators on regard our of the we note to months notes. and the very ovarian addressed convertible non-convertible half and to the that So actually and other in because

strength And and say do for reporting solid the to very this for clinical that that we to well fourth dedicated the be base. to go good. we point, investor convertible mentioned, have trial not a think, And that this we us allowed I diluting XXXX, pressure have currently some take has times obviously our going that's of off financial that's I the have, the should we financial basically As of Harry basically it's And – that our data. anything and think have to this money quarter our during be the I have, from huge, is notes. timelines not our especially runway through which a or – diverting to we at clinical

about are we very that. So happy

have with our a as we in pillar mentioned regard portfolio three and to for is of to slides and AGXXX, in have We according our a mentioned which instance, discussions very has even this prioritized exciting we near program the we have strategy feel that to that report served on X we for on a partnerships partnership, and best type look the in which are ongoing diabetes, the that our we future. forward

Jennifer Kim

again. congrats and much so Thanks helpful. Very right. All

Helen Sabzevari

Thank much. you very

Operator

At the session. conference remarks. Sabzevari to to question-and-answer turn back closing time, this for our I would Dr. This concludes like

Helen Sabzevari

update We very on Thank our communicating in the we be PRGN-XXXX further thank look you, Thank for announcement you much. in the forward and to our and touch will us to the near call. you time of join upcoming months. discussions for in taking future, for

Operator

for the presentation. concludes conference. This today's Thank you attending

You may disconnect. now

Precigen (PGEN) 9 Aug 222022 Q2 Earnings call transcript